Free Trial
NASDAQ:SRDX

Surmodics Q4 2024 Earnings Report

Surmodics logo
$27.00 -0.16 (-0.59%)
As of 02:04 PM Eastern

Surmodics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Surmodics Revenue Results

Actual Revenue
$33.23 million
Expected Revenue
$30.69 million
Beat/Miss
Beat by +$2.54 million
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
7:00AM ET

Surmodics Earnings Headlines

Analysts Set Expectations for Surmodics Q3 Earnings
Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX), together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

View Surmodics Profile

More Earnings Resources from MarketBeat